Regeneron and Zai Lab to develop and commercialize REGN1979 in China
Category: #headlines |   By Pankaj Singh |   Date: 2020-04-10  | 
  • Share
  • Twitter
  • Facebook
  • LinkedIn

Regeneron and Zai Lab to develop and commercialize REGN1979 in China

American biotechnology company Regeneron Pharmaceuticals is reportedly collaborating with Chinese biopharmaceutical firm Zai Lab Limited to develop and commercialize REGN1979 in mainland China, Taiwan, Hong Kong, and Macau.

REGN1979 is an advanced bispecific monoclonal antibody designed by Regeneron. It is developed to link and activate a lymphoma cell to a cytotoxic T-cell, triggering tumor killing.

As per terms of the deal, Regeneron will receive an upfront payment of US$30 million and will be eligible for an additional US$160 million in regulatory and sales milestones. Zai Lab will bear the expenses pertaining to global development of REGN1979 for several trials.

According to sources familiar with the matter, Regeneron will manufacture and supply REGN1979 for development and commercialization across regions. Zai Lab will obtain rights to develop and commercialize REGN1979 in mainland China, Taiwan, Macau, and Hong Kong. In addition, the company will also pay Regeneron depending upon net sales.

The partnership will foster the global clinical development of REGN1979, beginning with the current phase-2 trial in B-cell non-Hodgkin lymphoma (B-NHL). If approved, Zai Lab will commercialize REGN1979 in these regions.

With its regulatory and clinical expertise along with a notable commercial footprint in, Zai Lab could contribute substantially towards the success of REGN1979.

Also read: QIAGEN deploys QIAstat-Dx Respiratory SARS-CoV-2 test kits in Europe

Regeneron is renowned for its research, development and innovation in medical science, commented Samantha Du, Ph.D., founder, chairperson, and CEO of Zai Lab, adding that the company looks forward to working with the Regeneron group on REGN1979 as it expands its oncology franchise into hematologic cancers.

In collaboration with Regeneron, Zai Lab will look to expand its global effort and deliver innovative solutions to patients, Du added.

Zai Lab, according to Israel Lowy, M.D., Ph.D., Senior VP of Regeneron, is an ideal partner for Regeneron with an outstanding track record which aligns with Regeneron’s mission to leverage the power of science and deliver innovative medical products. Zai Lab will not only help boost the enrolment of REGN1979 into global trials but will also allow this promising investigational drug to reach patients faster, if approved, Lowy said.

 

Source: http://www.zailaboratory.com/in1/index.aspx

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with...

Read More

More News By Pankaj Singh

Deloitte Consulting announces acquisition of HashedIn Technologies
Deloitte Consulting announces acquisition of HashedIn Technologies
By Pankaj Singh

Cloud technologies have been gaining quite the recognition in the recent past, with several companies focusing on business-centric strategies such as acquisitions or collaborations or innovative product launches. One such company, HashedIn Technologi...

Xiaomi Mi 11 racks up strong profit, crosses 500K units in launch sale
Xiaomi Mi 11 racks up strong profit, crosses 500K units in launch sale
By Pankaj Singh

Chinese multinational electronics firm, Xiaomi Corporation, reportedly unveiled that it accrued revenue worth over USD 23,20,72,350 in a span of 5 minutes, after the first sale of its Mi 11 flagship smartphone, announced in December, which went live ...

Tata Group outlines expansion strategies of its aviation business
Tata Group outlines expansion strategies of its aviation business
By Pankaj Singh

Indian multinational conglomerate Tata Group has reportedly set up a strategy team led by Saurabh Agarwal, CFO, Tata Sons Pvt. Ltd., to explore options like mergers, alliance, and rebranding of its airline endeavors.  The company had recently a...